In order to evaluate the effecicney of rituximab combined with fludarabine,cyclophosphamide and rituximab(FCR) regimen for chronic lymphocytic leukemia(CLL).

The aim of this study was to compare the efficacy of rituximab plus CHOP regimen and CHOP regimen on newly diagnosed patients with diffuse large B-cell lymphoma(DLBCL),and analyze their toxicities.

Effectiveness and pharmacoeconomic evaluation of rituximab for treatment of non-Hodgkin s lymphoma;

Rituximab in Combination with CHOP Scheme for Non-Hodgkin s Lymphoma: Evaluation of Clinical Efficacy;

Expression of CD16ζ in NK Cells of B-cell Non-Hodgkin s Lymphoma Patients and In Vitro Killing Effect of Rituximab Combined Lymphokine-activated Killer Cells on B-NHL Cells;

Evaluation of Cetuximab in combination with radiotherapy or chemotherapy against advanced squamous cell carcinoma of the head and neck;

Effects of Cetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402;

Clinical observation of combination chemotherapy for metastatic colorectal cancer with Cetuximab;

Preparation and identification of monoclonal antibody against ginsenoside Rb1;

Development of monoclonal antibody against Fumonisin B_1 and ELISA-kit of quantitative analysis for Fumonisin B_1;

Determination of fipronil in water by ELISA based on monoclonal antibody;

Production and identification of monoclonal antibodies to chCD25;

Production and identification of monoclonal antibodies against proteinase activated receptor-1;

Expression and purification of recombinant nucleocapsid protein of SARS Coronavirus and preparation of its monoclonal antibodies;

Development and Characterization of MAb against Haemagglutinin of Highly Pathogenic H5 Avian Influenza Virus;

Preparation and characterization of non-agglutinating mAbs against membrane antigen on human erythrocytes;

Studies on the antithrombotic effects of anti-platelet mAb SZ-21 F(ab′)_2 fragment;